Literature DB >> 7138732

Patient subsets and variation in therapeutic efficacy.

R Simon.   

Abstract

1 The determination of what treatment is best for what kinds of patients is a general objective of clinical research. We consider here the extent to which this objective can be accomplished reliably in a single clinical trial. 2 The reliability of subset analyses is often poor due to problems of multiplicity and limitations in numbers of patients studied. Implications for the design of clinical trials are presented. 3 Statistical approaches to subset analysis are reviewed in a general manner. In order to obtain the degree of reliability usually demanded of clinical therapeutic evaluations, "statistically significant' interactions between relative treatment efficacy and subsets should be demonstrated. Exploratory analyses of subset differences are important but should be reported as hypotheses to be tested in separate studies.

Entities:  

Mesh:

Year:  1982        PMID: 7138732      PMCID: PMC1427603          DOI: 10.1111/j.1365-2125.1982.tb02015.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  The clinical trial.

Authors:  A B HILL
Journal:  Br Med Bull       Date:  1951       Impact factor: 4.291

3.  Randomized clinical trials.

Authors:  L Lasagna
Journal:  N Engl J Med       Date:  1976-11-04       Impact factor: 91.245

4.  Selecting optimal treatment in clinical trials using covariate information.

Authors:  D P Byar; D K Corle
Journal:  J Chronic Dis       Date:  1977-07

5.  Some thoughts on clinical trials, especially problems of multiplicity.

Authors:  J W Tukey
Journal:  Science       Date:  1977-11-18       Impact factor: 47.728

6.  Confidence intervals for the odds ratio in case-control studies: the state of the art.

Authors:  J L Fleiss
Journal:  J Chronic Dis       Date:  1979

7.  Influence of treatment adherence in the coronary drug project.

Authors: 
Journal:  N Engl J Med       Date:  1981-03-05       Impact factor: 91.245

8.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

9.  Allocation of patients to treatment in clinical trials.

Authors:  S J Pocock
Journal:  Biometrics       Date:  1979-03       Impact factor: 2.571

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

View more
  14 in total

Review 1.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

Review 2.  Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease.

Authors:  Rashmee U Shah; Tara I Chang; Gregg C Fonarow
Journal:  Heart Fail Clin       Date:  2012-10-16       Impact factor: 3.179

3.  Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.

Authors:  Iain Beehuat Tan; Tatiana Ivanova; Kiat Hon Lim; Chee Wee Ong; Niantao Deng; Julian Lee; Sze Huey Tan; Jeanie Wu; Ming Hui Lee; Chia Huey Ooi; Sun Young Rha; Wai Keong Wong; Alex Boussioutas; Khay Guan Yeoh; Jimmy So; Wei Peng Yong; Akira Tsuburaya; Heike Grabsch; Han Chong Toh; Steven Rozen; Jae Ho Cheong; Sung Hoon Noh; Wei Kiat Wan; Jaffer A Ajani; Ju-Seog Lee; Manuel Salto Tellez; Patrick Tan
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

4.  Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial.

Authors:  Sean P Collins; Christopher J Lindsell; Peter S Pang; Alan B Storrow; W Frank Peacock; Phil Levy; M Hossein Rahbar; Deborah Del Junco; Mihai Gheorghiade; Donald A Berry
Journal:  Am Heart J       Date:  2012-07-09       Impact factor: 4.749

5.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Treatment Heterogeneity and Individual Qualitative Interaction.

Authors:  Robert S Poulson; Gary L Gadbury; David B Allison
Journal:  Am Stat       Date:  2012-06-12       Impact factor: 8.710

7.  An indicator quantitatively comparing two treatment effect sizes on responder and non-responder groups--exponential of estimated interaction parameter.

Authors:  M Sugita; T Izuno; M Kanamori; K Ogoshi; T Mitomi
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

8.  Xiaoqinglong granules as add-on therapy for asthma: latent class analysis of symptom predictors of response.

Authors:  Qinglin Zha; Seqi Lin; Chi Zhang; Christopher Chang; Hanrong Xue; Cheng Lu; Miao Jiang; Yan Liu; Zuke Xiao; Weiyou Liu; Yunfei Shang; Jianjian Chen; Minyong Wen; Aiping Lu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-03       Impact factor: 2.629

Review 9.  Statistical aspects of prognostic factor studies in oncology.

Authors:  R Simon; D G Altman
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.